Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Zalifrelimab · AGEN1884, UGN-301

Monoclonal antibody · Antagonist of CTLA-4 · developed by Agenus

Phase 1/2 Most advanced trial

AGEN Developer

2 Registered trials

What is Zalifrelimab?

Zalifrelimab is a recombinant human monoclonal antibody that binds CTLA-4 on T cells and blocks its inhibitory signaling, enhancing cytotoxic T-lymphocyte-mediated immune responses against cancer. It is being studied in pancreatic ductal adenocarcinoma and cervical cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: AGEN1884, UGN-301
Drug type: Monoclonal antibody
Targets: CTLA-4
Mechanism: Antagonist of CTLA-4
Pathways: T-cell activation, immune checkpoint inhibition
Therapy area: Oncology
Developer: Agenus Inc. (AGEN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: FE7L22H028

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04827953	Phase 1/2	Pancreatic Ductal Adenocarcinoma	Active not recruiting	AGEN
NCT03894215	Phase 2	Cervical Cancer	Terminated	AGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pancreatic Ductal AdenocarcinomaCervical Cancer

Other drugs acting on CTLA4

Ipilimumab FDA approved Tremelimumab FDA approved Botensilimab Phase 2/3 Cadonilimab Early Phase 1 Firastotug Phase 1 Muzastotug Phase 2 Pembrolizumab/Quavonlimab Phase 1/2 Volrustomig Phase 3

More from Agenus

AGEN1223 Phase 1 AGEN1571 Phase 1 AGEN2017 Phase 1 AGEN2373 Phase 1/2 Balstilimab Phase 2/3 BMS-986442 Phase 1 Botensilimab Phase 2/3 QS21 Phase 2 Vitespen Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AGEN page.

Follow AGEN, the company behind Zalifrelimab

See AGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AGEN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z